News
Our New Technology Got U.S. Invention Patent License

Our New Technology Got U.S. Invention Patent License

On March 1st, 2016, the patent “antimicrobial peptide and methods of preparation and use” which was independently developed by Jiangsu ProteLight got the authorization of the U.S. invention patent license officially (patent license NO.US9, 273, 095B2 ).

06

2015

/

11

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

On September 21st, 2015, Wuxi Municipal Committee and Wuxi Municipal People’s Government hold the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”, which aims to expand the international perspective for Wuxi industrial development. Jiangsu ProteLight ‘s President Dr. Yuxin Chen, and Chief technical consultant Dr. Hartmut Michel were invited to attend the meeting and made speech there.

24

2015

/

09

ProteLight’s PL-5 was listed in Priority Review Varieties

ProteLight’s PL-5 was listed in Priority Review Varieties

National Health and Family Planning Commission of the P.R.C. intend to accelerate the production process of Key innovative new drug manufacture projects, key science and technology projects. The special implementation management office of Key innovative new drug manufacture projects propose to recommend 17 drugs, including ProteLight’s PL-5 as priority review varieties on basis on experts selecting suggestions.

15

2015

/

09

Warmly congratulations to establishment of Hartmut Michel Institute of (Jiangyin) Biomedical Research

Warmly congratulations to establishment of Hartmut Michel Institute of (Jiangyin) Biomedical Research

In the morning of November 18th, 2014, ProteLight together with the Noble Prize Winner Professor Hartmut Michel together established Hartmut Michel Institute of (Jiangyin) Biomedical Research, which is the third Noble Prize Winner research in Jiangyin. Zhou Tiegen, a member of Wuxi Municipal Committee and the secretary of Jiangyin Municipal Committee, Zhu Jinsong, a member of Wuxi Municipal Committee and minister of Wuxi Organization Department, and Shen Jian, the Vice-secretary of Jiangyin Municipal Committee and the Mayor of Jiangyin, attended this ceremony and made an important speech there. Before the meeting starts, together with the President of ProteLight, Dr. Yuxin Chen, the Secretary Zhou Tiegen, the Minister Zhu Jinsong and the Mayor Shen Jian had a face to face meeting with Professor Michel.

24

2014

/

11

Congratulate ProteLight got the title of “the most potential seed corporation” granted by 2014 EY Fudan in China

Congratulate ProteLight got the title of “the most potential seed corporation” granted by 2014 EY Fudan in China

The most Potential Corporation Award Ceremony of the Fourth Ernst & Young Fudan in China was held on September 16, 2014, in Shanghai. This selection was hold jointly by Ernst & Young, one of the world’s four largest accounting firms in economic area, and School of Management, Fudan University’s, one of the top universities. After expert team’s careful assessment and strict selection, the winning companies were selected out in the end.

23

2014

/

09

Two New Drugs of National Category 1.1 Got Clinical Acceptance Notification

Two New Drugs of National Category 1.1 Got Clinical Acceptance Notification

In May 2014, the clinical trial application of ProteLight’s two national category 1.1 new drugs, antimicrobial peptide PL-5 active pharmaceutical ingredient and its preparation accepted by Jilin FDA, and we got the notification of application acceptance for drug registration, that means the two drugs were in the process of registration application. Antimicrobial peptide PL-5 has clear intellectual property right protection, and is applicable to most of skin infections (including stubborn infectious disease initiated by drug resistant bacteria, such as diabetic foot and bed sore),. It is defined as a project of “12th five-year plan” key innovative new drug manufacture projects in 2012 and got support as“Science and Technology Innovation Fund (growth type)” project of Ministry of Science and Tehcnology.

04

2014

/

06

The Nobel Prize winner, Dr. Hartmut Michel came to visit and cooperate with our company

The Nobel Prize winner, Dr. Hartmut Michel came to visit and cooperate with our company

On April 27th, 2017, the Nobel Prize winner of 1998, Dr. Hartmut Michel came to visit Jiangsu ProteLight and talk about cooperation. Dr. Hartmut Michel is a biochemist, majors in membrane protein and membrane polypeptide research for a long time, and gets outstanding achievements in applying protein and polypeptide to pharmaceutical area. During the visit, Dr. Michel visited the work shop and Products Exhibition Hall, negotiated about cooperation, and met with leaders from Jiangyin Municipal Government and National Hi-Tech District.

14

2014

/

05

Jiangyin ProteLight changed its name to Jiangsu ProteLight

Jiangyin ProteLight changed its name to Jiangsu ProteLight

In order to adapt to corporation development planning and participate in market competition, Jiangyin ProteLight Pharmaceutical & Biotechnology Co., Ltd. changes its name to Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. from June 2012. We will continue to provide customers with honest, passionate and considerate service, to improve business management with developmental perspective, to build corporation image with honest operation, to create a brand with all staffs effort, to make a great achievement with world-class performance, and to be the most trusted and outstanding corporation in domestic industry. With ProteLight’s spirit, good traditions, practical style, satisfactory service and fruitful results to build an outstanding corporation brand and to get customers trust.

12

2012

/

06

< 12345 >